5-Bromo-N-(4,5-Dihydro-1H-Imidazol-2-yl)-6-QuinoxalinamineTartrate , ≥99% , 70359-46-5
Synonym(s):
Brimonidine tartrate
CAS NO.：70359-46-5
Empirical Formula: C15H16BrN5O6
Molecular Weight: 442.22
MDL number: MFCD07773072
EINECS: 629-848-5
| Pack Size | Price | Stock | Quantity |
| 50mg | RMB249.60 | In Stock |
|
| 250mg | RMB959.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 207-208°C (dec.) |
| storage temp. | Inert atmosphere,Store in freezer, under -20°C |
| solubility | DMSO: 1 mg/ml; PBS (pH 7.2): 3 mg/ml |
| form | Solid |
| color | White to off-white |
| InChIKey | QZHBYNSSDLTCRG-WUUYCOTASA-N |
Description and Uses
Brimonidine is an agonist of α2-adrenergic receptors (α2-ARs; Kis = 2.7, 52, and 44 nM for α2A, α2B, and α2C-ARs, respectively, in CHO cells). It is selective for α2-ARs over α1-ARs (Ki = 1,800 nM in human brain). Brimonidine lowers intraocular pressure in DBA/2J mice, a model of glaucoma, to control levels when applied topically to the eye as a 0.1% solution. It also inhibits glutamate release, prevents upregulation of NMDA receptors containing NR1 and NR2A subunits, and protects rat retinal ganglion cells against glutamate excitotoxicity in a rat model of retinal ischemia when administered at a dose of 1 mg/kg per day. Formulations containing brimonidine have been used in the treatment of open-angle glaucoma and ocular hypertension.
It is an α2 receptor agonist. It is a drug used to treat glaucoma.
Safety
| Symbol(GHS) |  GHS06 |
| Signal word | Danger |
| Hazard statements | H301-H315-H319-H335 |
| Precautionary statements | P261-P264-P270-P301+P310-P302+P352-P305+P351+P338 |
| RIDADR | UN 2811 6.1 / PGIII |
| HS Code | 29332900 |
